

1 **Title: Comparing the test performance of dried-blood-spot and plasma HIV**
2 **recent infection testing samples in a nationally scaled sex worker programme**
3 **in Zimbabwe**

4 **Authorship:** Brian D Rice¹, Harriet S Jones², Fortunate Machingura³, Leah Gaihai³, Memory
5 Makamba³, Thomas Chanyowedza³, Panganai Masvikeni³, Edward Matsikire³, Primrose
6 Matambanadzo³, Sithembile Musemburi³, Phillip N Chida³, Jeffery Dirawo³, Owen Mugurungi⁴,
7 Sarah Bourdin², James R Hargreaves², Gary Murphy⁵, Frances M Cowan^{3,6}

8 **Affiliations:**

- 9 1. University of Sheffield, School of Medicine and Population Health, Sheffield, United Kingdom
10 2. London School of Hygiene and Tropical Medicine, Faculty of Public Health and Policy,
11 London, United Kingdom
12 3. Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) Zimbabwe, Harare,
13 Zimbabwe
14 4. AIDS and TB Directorate, Ministry of Health and Child Care, Harare, Zimbabwe
15 5. Independent consultant, London, United Kingdom
16 6. Liverpool School of Tropical Medicine, Faculty of Global Health, Liverpool, United Kingdom

17 **Abstract**

18 Recency testing can provide strategic insights as to whether a person newly diagnosed with HIV
19 recently acquired their infection or not. To understand potential biases associated with HIV
20 recency testing, we explored the extent sample type influences whether a person is assigned as
21 being recent. Implementing a laboratory-based Recent Infection Testing Algorithm (RITA) across
22 the Centre for Sexual Health and HIV/AIDS Research (CeSHHAR) key populations programme
23 in Zimbabwe between October 2021 and January 2023, we compared plasma-based and dried-
24 bloodspot (DBS) HIV recency samples. Over the study period, 24,976 individual female sex

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 workers HIV tested, of whom 9.5% (2,363/24,979) newly tested HIV positive. Of these 2,363
26 women, 55.5% (1311/2,363) were offered and gave consent for a sample to be taken for DBS
27 recency and viral load testing, among whom 11.7% (153/1,311) were classified as having a recent
28 infection. A subset of 464 women were offered and consented to paired sample collection, among
29 whom 10.1% (47) and 12.3% (57) of plasma and DBS samples, respectively, were classified as
30 recent. Overall, categorical determination was good, with 97% of results concordant. Of 58 women
31 with paired sample collection who had a test result classified as recent, 46 (79.3%) were concordant
32 recent on both DBS and plasma, with 12 (20.7%) being dis-concordant. Of these 12 women's
33 samples, 11 were deemed long-standing by the plasma assay but recent by the paired DBS, and
34 one deemed long-standing by DBS but recent by the paired plasma sample. Depending on use-
35 case and setting, there are trade-offs when considering DBS or plasma-based samples between test
36 performance and ease of implementation. Our data can help inform statistical adjustments to
37 harmonise cut-offs on DBS and plasma assays, thereby improving the use and interpretation of
38 recency assays in population-level HIV surveillance activities.

39 **Introduction**

40 If we are to achieve sustainable HIV epidemic control, we need to better understand epidemic
41 dynamics and improve the efficiency of programme service delivery. In gaining strategic insights
42 of patterns and distributions of new HIV infections, and in prioritising prevention and testing
43 interventions, there has been much discussion about the use of recency testing in programmatic
44 setting [1-6]. Recency testing can help identify whether a person newly diagnosed with HIV
45 recently acquired their infection (usually <one year) or not [1]. As a disproportionate number of
46 HIV transmissions originate from people who have early HIV infection [7], identifying people or
47 populations with recent infections has strategic potential to inform where interventions should be
48 prioritised to reduce overall levels of transmission.

49 In relation to epidemic dynamics, it has been argued that there is a clear rationale for the use of
50 recency assays for population-level HIV incidence estimation [2]. However, in relation to helping
51 programmes focus limited resources to populations with the greatest potential benefit, it has been
52 contended that their application for non-incidence use cases remains questionable [2].

53 In previous research we have shown the pragmatic application of laboratory-based HIV recency
54 testing in programme settings in Kenya and Zimbabwe to be feasible [3,4]. Among calls for further
55 research to better understand the potential biases associated with HIV recency testing [1,2,5,6],
56 has been a request to explore the extent sample type influences whether a person is assigned as
57 being recent [8]. In the context of a national scaled sex worker programme in Zimbabwe we
58 explored whether conducting plasma-based HIV recency testing, in addition to our standard
59 approach using DBS, impacted on recent HIV infection classification.

60 **Methods**

61 We implemented a laboratory-based Recent Infection Testing Algorithm (RITA) across the Centre
62 for Sexual Health and HIV/AIDS Research (CeSHHAR) key populations programme (formerly
63 known as the Sisters with a Voice programme) in Zimbabwe between October 2021 and January
64 2023. The programme has been described elsewhere [9]. Since the programme's initiation in 2009,
65 HIV testing coverage has increased substantially and those attending services are likely to be
66 representative of female sex workers (FSW) in Zimbabwe [10-12].

67 All FSW testing newly HIV positive during the study period were eligible for enrolment in the
68 study if aged 18 years and older and having received a confirmatory HIV positive test result, in
69 line with Zimbabwe's national testing algorithm. Those under 18 years, with an indeterminate HIV
70 test result or prior history of testing HIV-positive, or reported as being in receipt of anti-retroviral
71 therapy, were excluded from enrolment. Informed consent was sought from all eligible women. A
72 DBS sample was collected for each consenting woman, with samples tested using the Maxim HIV-
73 1 Limiting Antigen Avidity (LAg Avidity) Enzyme Immunoassay (EIA) in accordance with the

74 product insert (DBS KIT CAT NO. 92003) [13]. Samples were stored at clinic sites at room
75 temperature in gas impermeable plastic bags with desiccant sachets to keep them dry. Samples
76 were collected from sites every 14 days by a designated study driver and delivered to the Flow
77 Cytometry Laboratory in Harare.

78 Ethylenediaminetetraacetic Acid (EDTA) whole blood samples were also collected from a sub-set
79 of consenting women at pre-identified Sisters clinics with the capacity for samples to reach the
80 laboratory within 24 hours. Sites collecting plasma samples stored these in cool boxes with
81 thermometers and trackers to monitor the temperature and timely delivery to the lab. Cooler boxes
82 were collected at the end of each day by a delivery company. At the laboratory, EDTA whole
83 blood samples were checked using quality control procedures and stored at 20 degrees Celsius.

84 Samples with a normalised optical density (OD_n) <2.0 underwent retesting in triplicate from a
85 fresh dilution of the specimen to confirm the HIV LAg result. Samples with a final OD_n >1.5
86 after retesting were classified as long-term HIV infection. Viral load testing was performed with
87 a NucliSens assay on anti-HIV-1 positive samples with a final OD_n ≤1.5. Samples with an OD_n
88 ≤1.5 and a viral load <1000 copies/ml denoted long-term infection, and those with an OD_n ≤1.5
89 and a viral load ≥1000 copies/ml were classified as recent infection. Those samples with an OD_n
90 of <0.4 were retested with an HIV-1 ELISA test to confirm they were HIV-1 seropositive.

91 **Results**

92 Over the study period, 24,976 individual FSW HIV tested at CeSHHAR programme clinics, of
93 whom 9.5% (2,363/24,979) newly tested HIV positive. Of these 2,363 women, 55.5%
94 (1311/2,363) were offered and gave consent for a sample to be taken for DBS recency and viral
95 load testing and were enrolled in the study. Among these women no samples were rejected, and
96 11.7% (153/1,311) were classified as having a recent infection.

97 Focusing on pre-identified clinics capable of plasma testing and transport, 464 women were
98 offered and consented to paired sample collection (i.e. DBS and plasma, and viral load). Among

99 these 464 women, plasma testing classified 10.1% (47) as having a recent infection, with DBS
 100 classifying 12.3% (57) (table 1). Of the 58 women with paired sample collection who had a test
 101 result classified as recent, 46 (79.3%) were concordant recent on both DBS and plasma, with 12
 102 (20.7%) being dis-concordant. Eleven samples were deemed long-standing by the plasma assay but
 103 recent by the paired DBS, and one deemed long-standing by DBS but recent by the paired plasma
 104 sample. Overall, there was 97.4% (452/464) concordance between the DBS and plasma samples.

105 **Table 1: RITA classification of plasma and DBS samples**

		DBS		
		Long-term	Recent	Total
Plasma	Long-term	406	11	417
	Recent	1	46	47
	Total	407	57	464

106 Figure 1 compares ODn values of plasma and DBS samples. Of the 12 samples that were not in
 107 agreement for recent infection classification (pink dots), 3 had very different ODn values. The
 108 remaining 9 fell close to either side of the 1.5ODn cut-off. Figure 2 shows that, on average, plasma
 109 samples had higher ODn by a mean difference of 0.53 ODn (SD 0.98). Tests however did not
 110 show consistent variance across the range of ODn values, with ODn agreement being better at
 111 values below 2.

112 **Figure 1: ODn values for plasma and DBS samples**

113

114 **Figure 2: Bland-Altman plot of plasma and DBS ODn on paired samples**

115

116 **Discussion**

117 To gain additional insights into routine HIV recent infection testing within a national scaled sex
 118 worker programme in Zimbabwe, we compared results using DBS and plasma samples. Overall,

119 categorical determination was good, with 97% of results concordant. However, we found the use
120 of different sample types impacted on recent HIV infection classification. On average, plasma
121 samples had a higher OD_n than DBS samples, with a mean difference of 0.53. This difference
122 resulted in a higher percentage of women being classified as recent positive on their DBS sample
123 versus plasma (12.2% versus 10.3%).

124 In a previous study test matching 100 plasma and DBS samples, DBS samples were more likely to
125 be classified as recent [8]. The study's authors suggested DBS protocols could be adjusted to
126 account for false recency results, or that appropriate changes to assay cut-offs could be applied to
127 account for the higher rate of recency positive test results arising from DBS. In relation to false
128 recency results, we were unable to explore this in our study beyond including a viral load in our
129 RITA. However, we can assume that both the plasma and DBS recent classified results are likely
130 to include misclassification. We previously reported in Siaya county in Western Kenya that of
131 eleven women classified as recent based on their LAg plasma samples and viral-load tests, one was
132 reclassified as long-standing after a review of clinical documentation that showed she had initiated
133 HIV treatment almost four years prior (recency misclassification of 9.1%) [3]. In Nairobi, Kenya,
134 we previously reported that of 48 people testing recent based on their DBS sample and viral load
135 one woman and one man were reclassified following antiretroviral therapy metabolite testing
136 (misclassification of 4.2%) [3]. In relation to applying assay cut-offs, our data (preferably in
137 combination with other complementary data) could be utilised to inform a statistical adjustment
138 to harmonise cut-offs on DBS and plasma samples.

139 When conducting recency testing using DBS or plasma for different use-cases [2], there are factors
140 in addition to test accuracy to be considered, for example implementation. In relation to three
141 pilot studies of HIV recency testing we previously conducted in Kenya and Zimbabwe, we
142 reported testing acceptance rates to differ by sample type (higher acceptance rates for DBS than
143 plasma) [3,4]. We also reported how DBS sample collection was simpler than plasma sampling, as

144 they could be transported and stored dry at room temperature (plasma requires maintenance of a
145 cold chain during transportation and storage) [4]. In implementing the collection of both sample
146 types, it was our experience in this study that DBS samples were easier to collect, transport and
147 store than plasma samples. However, we also found DBS samples to be less timely than plasma
148 due to the need for elution before testing. The issue of timeliness, however, was somewhat negated
149 by the necessity for all recency tests to be analysed alongside viral load results for validation. This
150 need for additional information, such as viral load, to interpret results, and to confirm HIV
151 diagnosis, also equalises potential time gains from adopting recency point-of-care tests over
152 laboratory-based testing for incidence estimation. We should note that concerns relating to low
153 sensitivity for the detection of recent infection have also been raised in relation to point-of-care
154 tests [14,15].

155 Laboratory-based recency testing, when conducted optimally, can distinguish recently acquired
156 infection from long-standing infection among persons newly diagnosed with HIV. Depending on
157 use-case and setting, however, there are trade-offs when considering DBS or plasma-based
158 samples between test performance and ease of implementation. In comparing DBS and plasma
159 test results, we present information that can improve the use and interpretation of recency assays
160 in population-level HIV surveillance activities.


161 **Acknowledgments**

162 We thank the women who enrolled in our study and those who visited CeSHHAR's Key
163 Populations programme during the study period, all contributing data to this analysis. We thank
164 everyone who has dedicated time to implementing CeSHHAR's Key Populations programme.

165 **References**


- 166 1. Joint United Nations Programme on HIV/AIDS and the World Health Organization. Using
167 Recency Assays for HIV Surveillance 2022 technical guidance. Final report. Geneva: Joint
168 United Nations Programme on HIV/AIDS and the World Health Organization; 2022.
- 169 2. Facente SN, Grebe E, Maher AD, Fox D, Scheer S, Mahy M, et al. Use of HIV Recency
170 Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.
171 JMIR Public Health Surveill. 2022;8(3):e34410.
- 172 3. Rice BD, de Wit M, Welty S, Risher K, Cowan FM, Murphy G, et al. Can HIV recent
173 infection surveillance help us better understand where primary prevention efforts should be
174 targeted? Results of three pilots integrating a recent infection testing algorithm into routine
175 programme activities in Kenya and Zimbabwe. J Int AIDS Soc. 2020;23 Suppl 3(Suppl
176 3):e25513.
- 177 4. de Wit MM, Rice B, Risher K, Welty S, Waruiru W, Magutshwa S, et al. Experiences and
178 lessons learned from the real-world implementation of an HIV recent infection testing
179 algorithm in three routine service-delivery settings in Kenya and Zimbabwe. BMC Health
180 Serv Res. 2021;21(1):596.
- 181 5. World Health Organization. Consolidated guidelines on person-centred HIV strategic
182 information: strengthening routine data for impact. Final report. Geneva: World Health
183 Organization; 2022.
- 184 6. amfAR. Blinded by Our Own Data - Recency Testing in PEPFAR. Washington DC: amfAR;
185 2022. Available from [https://www.amfar.org/wp-](https://www.amfar.org/wp-content/uploads/2022/05/amfar_recency_report_20220531.pdf)
186 [content/uploads/2022/05/amfar_recency_report_20220531.pdf](https://www.amfar.org/wp-content/uploads/2022/05/amfar_recency_report_20220531.pdf)
- 187 7. Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al. Brief but efficient:
188 acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189(10):1785-92.

- 189 8. Schlusser KE, Pilcher C, Kallas EG, Santos BR, Deeks SG, Facente S, et al. Comparison of
190 cross-sectional HIV incidence assay results from dried blood spots and plasma. PLoS One.
191 2017;12(2):e0172283.
- 192 9. Cowan FM, Chabata ST, Musemburi S, Fearon E, Davey C, Ndori-Mharadze T, et al.
193 Strengthening the scale-up and uptake of effective interventions for sex workers for
194 population impact in Zimbabwe. J Int AIDS Soc. 2019;22 Suppl 4(Suppl Suppl 4):e25320.
- 195 10. Cowan FM, Davey CB, Fearon E, Mushati P, Dirawo J, Cambiano V, et al. The HIV Care
196 Cascade Among Female Sex Workers in Zimbabwe: Results of a Population-Based Survey
197 From the Sisters Antiretroviral Therapy Programme for Prevention of HIV, an Integrated
198 Response (SAPPH-IRE) Trial. J Acquir Immune Defic Syndr. 2017;74:375–82.
- 199 11. Chabata ST, Fearon E, Webb EL, Weiss HA, Hargreaves JR, Cowan FM. Assessing Bias in
200 Population Size Estimates Among Hidden Populations When Using the Service Multiplier
201 Method Combined With Respondent-Driven Sampling Surveys: Survey Study. JMIR Public
202 Health Surveill. 2020;6: e15044.
- 203 12. Jones HS, Hensen B, Musemburi S, Chinyanganya L, Takaruza A, Chabata ST, et al.
204 Interpreting declines in HIV test positivity: an analysis of routine data from Zimbabwe's
205 national sex work programme, 2009-2019. J Int AIDS Soc. 2022;25(7):e25943.
- 206 13. MaximBio. Maxim HIV-1 Limiting Antigen Avidity EIA. Rockville, MD: 2024. Available
207 from <https://maximbio.com/covid-hiv-test-kit/hiv-1-limiting-antigen-eia/>
- 208 14. Galiwango RM, Ssuuna C, Kaleebu P, Kigozi G, Kagaayi J, Nakigozi G, et al. Validation of
209 the Asante HIV-1 Rapid Recency Assay for Detection of Recent HIV-1 Infections in
210 Uganda. AIDS Res Hum Retroviruses. 2021;37(12):893-896.
- 211 15. Singh B, Mthombeni J, Olorunfemi G, Goosen M, Cutler E, Julius H, et al. Evaluation of the
212 accuracy of the Asanté assay as a point-of-care rapid test for HIV-1 recent infections using
213 serum bank specimens from blood donors in South Africa, July 2018 - August 2021. S Afr
214 Med J. 2023;113(10):42-48.



Figure

medRxiv preprint doi: <https://doi.org/10.1101/2024.09.13.24313626>; this version posted September 14, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



Figure